N-of-1 trials in cancer drug development

• Verfasst von: Gouda, Mohamed A. [VerfasserIn]
• Verfasst von: Buschhorn, Lars [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Verfasst von: Wahida, Adam [VerfasserIn]
• Verfasst von: Subbiah, Vivek [VerfasserIn]
• Titel: N-of-1 trials in cancer drug development
• Verf.angabe: Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, and Vivek Subbiah
• E-Jahr: 2023
• Jahr: 1 June 2023
• Umfang: 9 S.
• Fussnoten: Gesehen am 24.07.2023
• Titel Quelle: Enthalten in: Cancer discovery
• Ort Quelle: Philadelphia, Pa. : [Verlag nicht ermittelbar], 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), 6 vom: Juni, Seite 1301-1309
• ISSN Quelle: 2159-8290
• DOI: doi:10.1158/2159-8290.CD-22-1377
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1853470376

Abstract

The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are several considerations before its broad application becomes feasible. In essence, N-of-1 trials are a departure from the traditional “drug-centric” model to a “patient-centric” model. Herein, we review the concept of N-of-1 trials and provide real-world examples of their use in the developmental therapeutics field. N-of-1 trials offer an exceptional opportunity for fast-tracking of cancer drug development in the precision oncology era.